Sarker Bipul Kumer De, Abdullahi Sadiq M, Hassan Zafrul, Kabir Jahangir, Badmus Sarat, Alam Sarwar, Rahman Mostafizur, Malek Mohammad I, Mahatma Mallika
1 Glaucoma, Ispahani Islamia Eye Institute and Hospital, Dhaka, Bangladesh.
2 Paediatric and Strabismus, Ispahani Islamia Eye Institute and Hospital, Dhaka, Bangladesh.
Eur J Ophthalmol. 2019 Mar;29(2):183-188. doi: 10.1177/1120672118771841. Epub 2018 Apr 27.
: To compare the efficacy and safety of trabeculectomy with Ologen versus Mitomycin C in primary glaucoma.
: This is a prospective study of patients aged 18 years and above, diagnosed with primary glaucoma randomised to having trabeculectomy with Ologen or Mitomycin C. The primary outcome measure was success of trabeculectomy defined as intraocular pressure >5 mmHg but ≤21 mmHg. Complete success was defined as intraocular pressure achieved without anti-glaucoma medication and qualified success was defined as intraocular pressure achieved with additional anti-glaucoma medication.
: At the end of 12 months follow-up, the postoperative mean intraocular pressure in the Ologen group was 12.8 ± 1.6 mmHg and 13.4 ± 2.2 mmHg in the Mitomycin C group. The Ologen group achieved complete success in 86.5% and qualified success in 13.5% of the patients, while the Mitomycin C group achieved complete and qualified success in 85.5% and 14.5%, respectively. There was no statistically significant difference in the success rate of both the groups ( p = 0.57). Furthermore, no significant intraocular pressure difference was noted between the two groups at the end of 12 months follow-up ( p = 0.14).
: Trabeculectomy augmented with Ologen appeared to be as successful and safe as trabeculectomy augmented with Mitomycin C, with no reported adverse reaction to Ologen.
比较原发性青光眼患者行Ologen小梁切除术与丝裂霉素C小梁切除术的疗效和安全性。
这是一项针对18岁及以上原发性青光眼患者的前瞻性研究,患者被随机分为接受Ologen小梁切除术或丝裂霉素C小梁切除术。主要结局指标是小梁切除术的成功,定义为眼压>5 mmHg但≤21 mmHg。完全成功定义为无需使用抗青光眼药物即可达到的眼压,合格成功定义为需额外使用抗青光眼药物才能达到的眼压。
在12个月的随访结束时,Ologen组术后平均眼压为12.8±1.6 mmHg,丝裂霉素C组为13.4±2.2 mmHg。Ologen组86.5%的患者获得完全成功,13.5%的患者获得合格成功,而丝裂霉素C组分别为85.5%和14.5%。两组成功率无统计学显著差异(p = 0.57)。此外,在12个月随访结束时,两组之间未发现显著的眼压差异(p = 0.14)。
Ologen辅助小梁切除术似乎与丝裂霉素C辅助小梁切除术一样成功和安全,且未报告对Ologen的不良反应。